Semin Respir Crit Care Med 2019; 40(02): 255-270
DOI: 10.1055/s-0039-1685187
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Lung Diseases in Inflammatory Myopathies

Thomas Barba
1   Department of Internal Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
,
Sabine Mainbourg
2   Department of Internal Medicine, Hôpital Lyon Sud, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
,
3   National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, UMR754, Claude Bernard University Lyon 1, Lyon, France
,
Jean-Christophe Lega
2   Department of Internal Medicine, Hôpital Lyon Sud, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
,
3   National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, UMR754, Claude Bernard University Lyon 1, Lyon, France
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2019 (online)

Abstract

Lung involvement is the leading cause of mortality in inflammatory myopathy. A careful assessment of clinical and serologic manifestations especially myositis-associated autoantibodies allows precise classification of the different phenotypes of inflammatory myopathy and stratification of the risk of lung involvement. About three out of four patients with inflammatory myopathy develop interstitial lung disease (ILD), which represents the main cause of morbidity and mortality. In patients with a confirmed diagnosis of inflammatory myopathy, the approach to the diagnosis of ILD includes assessment of clinical and functional severity, evaluation of the high-resolution computed tomography pattern of disease, which often suggests nonspecific interstitial pneumonia or organizing pneumonia. Bronchoalveolar lavage to rule out infection is often performed; however, video-assisted thoracoscopic lung biopsy is now generally discouraged, unless malignancy is suspected. The so-called antisynthetase syndrome characterized by the combination of mechanics' hands, Raynaud' phenomenon, myositis often mild or absent, and presence of one of the anti-tRNA synthetase antibodies is associated with a 70% risk of ILD, especially in subjects with antibodies other than anti-Jo1 antibodies (i.e., anti-PL7 or -PL12 antibodies). Treatment depends on both severity and progression of ILD, often including a combination of corticosteroids and immunosuppressive therapy. Rituximab-based regimen has showed promising results in retrospective studies for the management of refractory or rapidly progressive forms of ILD. Clinical trials are ongoing to evaluate the actual efficacy of this strategy on mortality related to lung disease. Secondary pulmonary complications of inflammatory myopathy include opportunistic infections, aspiration pneumonia, pneumomediastinum, ventilatory failure due to diaphragmatic muscular weakness, drug-induced pneumonitis, and rarely pulmonary hypertension.

 
  • References

  • 1 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (07) 344-347
  • 2 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (08) 403-407
  • 3 Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015; 54 (01) 50-63
  • 4 Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015; 24 (136) 216-238
  • 5 Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; 17 (09) 816-828
  • 6 Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M. , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22 (02) 245-250
  • 7 Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 2010; 6 (02) 108-119
  • 8 Hervier B, Devilliers H, Stanciu R. , et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12 (02) 210-217
  • 9 Prieto S, Grau JM. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010; 9 (05) A330-A334
  • 10 Oddis CV, Conte CG, Steen VD, Medsger Jr TA. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17 (10) 1329-1334
  • 11 Pearson C. Arthritis and Allied Conditions: a Textbook of Rheumatology, 9th ed. Philadelphia: Lea & Febiger; 1979
  • 12 Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372 (18) 1734-1747
  • 13 Hoogendijk JE, Amato AA, Lecky BR. , et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14 (05) 337-345
  • 14 Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016; 280 (01) 8-23
  • 15 Fiorentino DF, Chung LS, Christopher-Stine L. , et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65 (11) 2954-2962
  • 16 Sato S, Hirakata M, Kuwana M. , et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52 (05) 1571-1576
  • 17 Ghirardello A, Bassi N, Palma L. , et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013; 15 (06) 335
  • 18 Hall JC, Casciola-Rosen L, Samedy LA. , et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65 (08) 1307-1315
  • 19 Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A. , et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290797
  • 20 Ikeda S, Arita M, Morita M. , et al. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?. BMC Pulm Med 2015; 15: 159
  • 21 Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68 (05) 689-694
  • 22 Tanizawa K, Handa T, Nakashima R. , et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013; 107 (05) 745-752
  • 23 Li T, Guo L, Chen Z. , et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 2016; 6: 33226
  • 24 Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13 (4-5): 367-371
  • 25 Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-153
  • 26 Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91 (06) 2556-2564
  • 27 Gelpí C, Kanterewicz E, Gratacos J, Targoff IN, Rodríguez-Sánchez JL. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996; 39 (04) 692-697
  • 28 Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006; 73 (06) 646-654
  • 29 Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA. , et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 2017; 56 (06) 999-1007
  • 30 Lilleker JB, Vencovsky J, Wang G. , et al; all EuroMyositis contributors. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018; 77 (01) 30-39
  • 31 Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A. , et al; IIM Study Group and Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 2016; 46 (02) 225-231
  • 32 Lega JC, Fabien N, Reynaud Q. , et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13 (09) 883-891
  • 33 Rigolet A, Musset L, Dubourg O. , et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 2012; 91 (02) 95-102
  • 34 Guillen-Del Castillo A, Pilar Simeón-Aznar C, Fonollosa-Pla V. , et al. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin Arthritis Rheum 2014; 44 (03) 331-337
  • 35 Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?. J Rheumatol 2010; 37 (05) 1000-1009
  • 36 Marie I, Lahaxe L, Benveniste O. , et al. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162 (02) 337-344
  • 37 Watanabe Y, Uruha A, Suzuki S. , et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1038-1044
  • 38 Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62 (09) 2757-2766
  • 39 Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 1986; 83 (24) 9507-9511
  • 40 Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63 (03) 297-301
  • 41 Marie I, Hachulla E, Chérin P. , et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47 (06) 614-622
  • 42 Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X. , et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14 (07) 534-542
  • 43 Tani K, Tomioka R, Sato K. , et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest 2007; 54 (3-4): 295-302
  • 44 Kang EH, Lee EB, Shin KC. , et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44 (10) 1282-1286
  • 45 Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010; 138 (06) 1464-1474
  • 46 Fathi M, Vikgren J, Boijsen M. , et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59 (05) 677-685
  • 47 Tillie-Leblond I, Wislez M, Valeyre D. , et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63 (01) 53-59
  • 48 Fischer A, Antoniou KM, Brown KK. , et al; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46 (04) 976-987
  • 49 Yoshifuji H, Fujii T, Kobayashi S. , et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39 (03) 233-241
  • 50 Ye S, Chen XX, Lu XY. , et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26 (10) 1647-1654
  • 51 Gerfaud-Valentin M, Ahmad K, Piegay F. , et al. [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies]. Rev Mal Respir 2014; 31 (09) 849-853
  • 52 Kobayashi N, Takezaki S, Kobayashi I. , et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 2015; 54 (05) 784-791
  • 53 Hozumi H, Enomoto N, Kono M. , et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One 2015; 10 (03) e0120313
  • 54 Ichimura Y, Matsushita T, Hamaguchi Y. , et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71 (05) 710-713
  • 55 Trallero-Araguás E, Rodrigo-Pendás JA, Selva-O'Callaghan A. , et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64 (02) 523-532
  • 56 Yang H, Peng Q, Yin L. , et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 2017; 19 (01) 259
  • 57 Raghu G, Collard HR, Egan JJ. , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (06) 788-824
  • 58 Raghu G, Remy-Jardin M, Myers JL. , et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198 (05) e44-e68
  • 59 Douglas WW, Tazelaar HD, Hartman TE. , et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164 (07) 1182-1185
  • 60 Zare Mehrjardi M, Kahkouee S, Pourabdollah M. Radio-pathological correlation of organizing pneumonia (OP): a pictorial review. Br J Radiol 2017; 90 (1071): 20160723
  • 61 Tansey D, Wells AU, Colby TV. , et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44 (06) 585-596
  • 62 Todd NW, Marciniak ET, Sachdeva A. , et al. Organizing pneumonia/non-specific interstitial pneumonia overlap is associated with unfavorable lung disease progression. Respir Med 2015; 109 (11) 1460-1468
  • 63 Mejía M, Herrera-Bringas D, Pérez-Román DI. , et al. Interstitial lung disease and myositis-specific and associated autoantibodies: clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF). Respir Med 2017; 123: 79-86
  • 64 Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169 (01) 83-87
  • 65 Marie I, Josse S, Decaux O. , et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012; 11 (10) 739-745
  • 66 Debray MP, Borie R, Revel MP. , et al. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 2015; 84 (03) 516-523
  • 67 Marie I, Josse S, Hatron PY. , et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65 (05) 800-808
  • 68 Aggarwal R, McBurney C, Schneider F. , et al. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. Rheumatology (Oxford) 2017; 56 (03) 384-389
  • 69 Chung JH, Cox CW, Montner SM. , et al. CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis. AJR Am J Roentgenol 2018; 210 (02) 307-313
  • 70 Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38: 616-623
  • 71 American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166: 518-624
  • 72 Fujisawa T, Suda T, Nakamura Y. , et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32 (01) 58-64
  • 73 Won Huh J, Soon Kim D, Keun Lee C. , et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101 (08) 1761-1769
  • 74 Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136 (01) 23-30
  • 75 Barba T, Fort R, Cottin V. , et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 2018
  • 76 Leitner J, Drobits K, Pickl WF, Majdic O, Zlabinger G, Steinberger P. The effects of cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett 2011; 140 (1-2): 74-80
  • 77 Marie I, Josse S, Decaux O. , et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013; 24 (05) 474-479
  • 78 Marie I, Josse S, Hatron PY. , et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65 (05) 800-808
  • 79 Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62 (10) 1496-1501
  • 80 Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011; 11 (01) 6-13
  • 81 Fischer A, Brown KK, Du Bois RM. , et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40 (05) 640-646
  • 82 Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011; 70 (01) 86-91
  • 83 Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38 (05) 383-392
  • 84 Ideura G, Hanaoka M, Koizumi T. , et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007; 101 (07) 1406-1411
  • 85 Koreeda Y, Higashimoto I, Yamamoto M. , et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49 (05) 361-369
  • 86 Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012; 11 (05) 335-340
  • 87 Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X, Trallero-Araguás E, Labrador-Horrillo M, Vilardell-Tarrés M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013; 31 (03) 436-439
  • 88 Kurita T, Yasuda S, Oba K. , et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 2015; 54 (01) 39-44
  • 89 Sharma N, Putman MS, Vij R, Strek ME, Dua A. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol 2017; 44 (11) 1612-1618
  • 90 Keir GJ, Maher TM, Ming D. , et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014; 19 (03) 353-359
  • 91 Andersson H, Sem M, Lund MB. , et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015; 54 (08) 1420-1428
  • 92 Sharp C, McCabe M, Dodds N. , et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford) 2016; 55 (07) 1318-1324
  • 93 Doyle TJ, Dhillon N, Madan R. , et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol 2018; 45 (06) 841-850
  • 94 Saunders P, Tsipouri V, Keir GJ. , et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 2017; 18 (01) 275
  • 95 Cottin V, Nunes H, Brillet PY. , et al; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM“O”P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26 (04) 586-593
  • 96 Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. In: Cottin V, Cordier JF, Richeldi L. , eds. Orphan Lung Disease: A Clinical Guide to Rare Lung Disease. London: Springer Verlag; 2015: 327-47
  • 97 Cottin V, Le Pavec J, Prévot G. , et al; GERM“O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35 (01) 105-111
  • 98 Cottin V, Hansell DM, Sverzellati N. , et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017; 196 (09) 1162-1171
  • 99 Cottin V, Nunes H, Mouthon L. , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63 (01) 295-304
  • 100 Champtiaux N, Cottin V, Chassagnon G. , et al; Groupe d'Etudes et de Recherche sur les Maladies « Orphelines » pulmonaires (GERM«O»P). Combined pulmonary fibrosis and emphysema in systemic sclerosis: a syndrome associated with heavy morbidity and mortality. Semin Arthritis Rheum 2018; S0049-0172(17)30511-5
  • 101 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
  • 102 Sanges S, Yelnik CM, Sitbon O. , et al. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: data from the French pulmonary hypertension registry and review of the literature. Medicine (Baltimore) 2016; 95 (39) e4911
  • 103 Seeger W, Adir Y, Barberà JA. , et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62 (25, Suppl): D109-D116
  • 104 Nathan SD, Barbera JA, Gaine SP. , et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53 (01) 53
  • 105 Hervier B, Meyer A, Dieval C. , et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42 (05) 1271-1282
  • 106 Le Goff B, Chérin P, Cantagrel A. , et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61 (01) 108-118
  • 107 Chen L, Hu Y, Yao Y. , et al. [Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease]. Zhonghua Er Ke Za Zhi 2012; 50 (06) 465-469
  • 108 Dogra S, Suri D, Shah R, Rawat A, Singh S, Sodhi KS. Spontaneous pneumomediastinum: a rare complication of juvenile dermatomyositis. Int J Rheum Dis 2012; 15 (05) e131-e133
  • 109 Ye Q, Zhang L, Tian X, Shi J. Exacerbation of pneumomediastinum after air travel in a patient with dermatomyositis. Aviat Space Environ Med 2011; 82 (07) 734-736
  • 110 Cozzani E, Cinotti E, Felletti R, Pelucco D, Rebora A, Parodi A. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol 2013; 35 (06) 687-692
  • 111 Onishi S, Ono F, Hasegawa H, Yasukawa M. Pneumomediastinum and massive subcutaneous emphysema associated with dermatomyositis. Intern Med 2012; 51 (24) 3449-3450
  • 112 Rodrigues AJ, Jacomelli M, Scordamaglio PR, Figueiredo VR. Spontaneous pneumomediastinum associated with laryngeal lesions and tracheal ulcer in dermatomyositis. Rev Bras Reumatol 2012; 52 (05) 796-799
  • 113 Kartik S, Bhakuni DS, Shanmuganandan K. Continuous diaphragm sign in amyopathic dermatomyositis. Joint Bone Spine 2013; 80 (01) 102-103
  • 114 Saraya T, Tanaka Y, Ohkuma K. , et al. Massive tension pneumomediastinum. Intern Med 2012; 51 (06) 677
  • 115 Sandhya P, Keshava SN, Danda D, Padhan P, Mathew J, Gibikote S. Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 2012; 32 (05) 1415-1419
  • 116 Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59 (05) 372-376
  • 117 Marie I, Ménard JF, Hachulla E. , et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011; 41 (01) 48-60
  • 118 Redondo-Benito A, Curran A, Villar-Gomez A. , et al. Opportunistic infections in patients with idiopathic inflammatory myopathies. Int J Rheum Dis 2018; 21 (02) 487-496
  • 119 Suresh E, Wimalaratna S. Proximal myopathy: diagnostic approach and initial management. Postgrad Med J 2013; 89 (1054): 470-477
  • 120 Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 2010; 31 (03) 501-512
  • 121 Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 2014; 13 (10) 1048-1054
  • 122 Agrawal CS, Behari M, Shrivastava S, Ahuja GK, Bhandari S, Kothari SS. The heart in polymyositis-dermatomyositis. J Neurol 1989; 236 (04) 249-250
  • 123 Ungprasert P, Suksaranjit P, Spanuchart I, Leeaphorn N, Permpalung N. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014; 44 (01) 63-67
  • 124 Péter A, Balogh Á, Szilágyi S. , et al. Echocardiographic abnormalities in new-onset polymyositis/dermatomyositis. J Rheumatol 2015; 42 (02) 272-281
  • 125 Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L. , et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 1996; 14 (04) 373-379
  • 126 Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J-F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63 (11) 3439-3447
  • 127 Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52 (08) 2439-2446
  • 128 Yamasaki Y, Yamada H, Yamasaki M. , et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46 (01) 124-130